Fulgent Genetics, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Fulgent Stockholders’ Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Additional Paid-In Capital | Accumulated Other Comprehensive(Loss) Income | Retained Earnings | Fulgent Stockholders’ Equity | Noncontrolling Interest | Total Equity | |
| Balance at December 31, 2024 | 30,841 | $3 | $543,126 | $(368) | $590,467 | $1,133,228 | $(4,069) | $1,129,159 |
| Equity-based compensation | — | — | 10,550 | — | — | 10,550 | — | 10,550 |
| Restricted stock awards | 360 | — | — | — | — | — | — | — |
| Common stock withholding for employee tax obligations | (111) | — | (1,887) | — | — | (1,887) | — | (1,887) |
| Repurchase of common stock | (469) | — | (7,886) | — | — | (7,886) | — | (7,886) |
| Other comprehensive income, net | — | — | — | 4,703 | — | 4,703 | 30 | 4,733 |
| Net loss | — | — | — | — | (11,530) | (11,530) | (369) | (11,899) |
| Balance at March 31, 2025 | 30,621 | $3 | $543,903 | $4,335 | $578,937 | $1,127,178 | $(4,408) | $1,122,770 |
| Equity-based compensation | — | — | 10,039 | — | — | 10,039 | — | 10,039 |
| Restricted stock awards | 182 | — | — | — | — | — | — | — |
| Common stock withholding for employee tax obligations | (18) | — | (345) | — | — | (345) | — | (345) |
| Repurchase of common stock | (177) | — | (2,998) | — | — | (2,998) | — | (2,998) |
| Other comprehensive income (loss), net | — | — | — | 1,663 | — | 1,663 | (237) | 1,426 |
| Net loss | — | — | — | — | (18,957) | (18,957) | (299) | (19,256) |
| Balance at June 30, 2025 | 30,608 | $3 | $550,599 | $5,998 | $559,980 | $1,116,580 | $(4,944) | $1,111,636 |
| Equity-based compensation | — | — | 9,717 | — | — | 9,717 | — | 9,717 |
| Restricted stock awards | 264 | — | — | — | — | — | — | — |
| Common stock withholding for employee tax obligations | (18) | — | (357) | — | — | (357) | — | (357) |
| Contingently issuable shares in a business combination (1) | — | — | 5,731 | — | — | 5,731 | — | 5,731 |
| Other comprehensive income, net | — | — | — | 825 | — | 825 | 31 | 856 |
| Net loss | — | — | — | — | (6,608) | (6,608) | (218) | (6,826) |
| Balance at September 30, 2025 | 30,854 | $3 | $565,690 | $6,823 | $553,372 | $1,125,888 | $(5,131) | $1,120,757 |
(1)The Company agreed to issue up to 292,682 shares of the Company’s common stock in the acquisition of ANP Technologies, Inc., or ANP, upon achieving certain cash receipts. $5.7 million represented the fair value of the shares on the acquisition date. As of September 30, 2025, no common stock has been issued as the milestones have not been met. See details in Note 15. Business Combinations.
Condensed Consolidated Statements of Stockholders’ Equity
| Fulgent Stockholders’ Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares (1) | Amount | Additional Paid-In Capital | Accumulated Other ComprehensiveIncome (Loss) | Retained Earnings | Fulgent Stockholders’ Equity | Noncontrolling Interest | Total Equity | |
| Balance at December 31, 2023 | 29,653 | $3 | $501,718 | $1,205 | $633,175 | $1,136,101 | $(2,815) | $1,133,286 |
| Equity-based compensation | — | — | 11,518 | — | — | 11,518 | — | 11,518 |
| Exercise of common stock options | 1 | — | — | — | — | — | — | — |
| Restricted stock awards | 315 | — | — | — | — | — | — | — |
| Common stock withholding for employee tax obligations | (69) | — | (1,682) | — | — | (1,682) | — | (1,682) |
| Repurchase of common stock | (10) | — | (225) | — | — | (225) | — | (225) |
| Other comprehensive loss, net | — | — | — | (2,307) | — | (2,307) | (98) | (2,405) |
| Net loss | — | — | — | — | (13,462) | (13,462) | (384) | (13,846) |
| Balance at March 31, 2024 | 29,890 | $3 | $511,329 | $(1,102) | $619,713 | $1,129,943 | $(3,297) | $1,126,646 |
| Equity-based compensation | — | — | 11,635 | — | — | 11,635 | — | 11,635 |
| Restricted stock awards | 212 | — | — | — | — | — | — | — |
| Common stock withholding for employee tax obligations | (26) | — | (544) | — | — | (544) | — | (544) |
| Common stock issued in a business combination (1) | 186 | — | — | — | — | — | — | — |
| Other comprehensive income (loss), net | — | — | — | 225 | — | 225 | (24) | 201 |
| Net loss | — | — | — | — | (8,710) | (8,710) | (380) | (9,090) |
| Balance at June 30, 2024 | 30,262 | $3 | $522,420 | $(877) | $611,003 | $1,132,549 | $(3,701) | $1,128,848 |
| Equity-based compensation | — | — | 10,920 | — | — | 10,920 | — | 10,920 |
| Restricted stock awards | 293 | — | — | — | — | — | — | — |
| Common stock withholding for employee tax obligations | (18) | — | (431) | — | — | (431) | — | (431) |
| Other comprehensive income, net | — | — | — | 10,055 | — | 10,055 | 200 | 10,255 |
| Net loss | — | — | — | — | (14,648) | (14,648) | (46) | (14,694) |
| Balance at September 30, 2024 | 30,537 | $3 | $532,909 | $9,178 | $596,355 | $1,138,445 | $(3,547) | $1,134,898 |
(1)185,503 shares of the Company’s common stock were issued in May 2024 by the Company upon expiration of hold back provisions in connection with the business combination of Fulgent Pharma Holdings, Inc., or Fulgent Pharma, in 2022.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.